Theravance Biopharma Inc. (TBPH)
NASDAQ · Healthcare
Theravance Biopharma Inc. Long Term Debt 2012–2025
Theravance Biopharma Inc. annual/quarterly long term debt history from 2017 to 2021. Long term debt refers to financial obligations that are due more than one year in the future.
- Theravance Biopharma Inc. long term debt for the quarter ending December 31, 2021 were 616.3M, a 0.46% decrease year-over-year.
- Theravance Biopharma Inc. long term debt for 2021 were 616.3M, a 0.46% decrease from 2020.
- Theravance Biopharma Inc. long term debt for 2020 were 619.2M, a 36.07% increase from 2019.
- Theravance Biopharma Inc. long term debt for 2019 were 455.0M, a 0.15% increase from 2018.
- Theravance Biopharma Inc. long term debt for 2018 were 454.4M.
Long Term Debt
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| Theravance Biopharma Inc. Annual Long Term Debt (Millions of US $) | |
|---|---|
| 2021 | $616 |
| 2020 | $619 |
| 2019 | $455 |
| 2018 | $454 |
| 2017 | $224 |
| Theravance Biopharma Inc. Quarterly Long Term Debt (Millions of US $) | |
|---|---|
| 2021-12-31 | $616 |
| 2020-12-31 | $619 |
| 2019-12-31 | $455 |
| 2018-12-31 | $454 |
| 2017-12-31 | $224 |
Theravance Biopharma Inc. Long Term Debt — FAQ
Theravance Biopharma Inc. (TBPH) long term debt over the last 14 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see TBPH's long term debt history?
The chart and table above show Theravance Biopharma Inc.'s long term debt by year and by quarter, including the growth rate.